ZA947949B - Therapeutic agents - Google Patents
Therapeutic agentsInfo
- Publication number
- ZA947949B ZA947949B ZA947949A ZA947949A ZA947949B ZA 947949 B ZA947949 B ZA 947949B ZA 947949 A ZA947949 A ZA 947949A ZA 947949 A ZA947949 A ZA 947949A ZA 947949 B ZA947949 B ZA 947949B
- Authority
- ZA
- South Africa
- Prior art keywords
- alkyl
- halo
- cyano
- hydroxy
- optionally substituted
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- -1 cyano, hydroxy Chemical group 0.000 abstract 5
- 125000005843 halogen group Chemical group 0.000 abstract 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- 125000001589 carboacyl group Chemical group 0.000 abstract 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 3
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 abstract 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 abstract 2
- 206010010904 Convulsion Diseases 0.000 abstract 1
- 206010019196 Head injury Diseases 0.000 abstract 1
- 208000032843 Hemorrhage Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB939321162A GB9321162D0 (en) | 1993-10-13 | 1993-10-13 | Therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA947949B true ZA947949B (en) | 1996-01-23 |
Family
ID=10743505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA947949A ZA947949B (en) | 1993-10-13 | 1994-10-12 | Therapeutic agents |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US5753665A (OSRAM) |
| EP (1) | EP0723546B1 (OSRAM) |
| JP (1) | JPH09503771A (OSRAM) |
| CN (1) | CN1040537C (OSRAM) |
| AT (1) | ATE188966T1 (OSRAM) |
| AU (1) | AU679573B2 (OSRAM) |
| BG (1) | BG62405B1 (OSRAM) |
| BR (1) | BR9407812A (OSRAM) |
| CA (1) | CA2173857A1 (OSRAM) |
| CZ (1) | CZ106996A3 (OSRAM) |
| DE (1) | DE69422724T2 (OSRAM) |
| DK (1) | DK0723546T3 (OSRAM) |
| ES (1) | ES2142413T3 (OSRAM) |
| FI (1) | FI961630A0 (OSRAM) |
| GB (1) | GB9321162D0 (OSRAM) |
| GR (1) | GR3032480T3 (OSRAM) |
| HU (1) | HUT74580A (OSRAM) |
| IL (1) | IL111259A (OSRAM) |
| IN (1) | IN179169B (OSRAM) |
| MY (1) | MY112110A (OSRAM) |
| NO (1) | NO306509B1 (OSRAM) |
| NZ (1) | NZ274500A (OSRAM) |
| PL (1) | PL177920B1 (OSRAM) |
| PT (1) | PT723546E (OSRAM) |
| RO (1) | RO117020B1 (OSRAM) |
| RU (1) | RU2136684C1 (OSRAM) |
| SK (1) | SK282329B6 (OSRAM) |
| TW (1) | TW372237B (OSRAM) |
| UA (1) | UA42738C2 (OSRAM) |
| WO (1) | WO1995010521A1 (OSRAM) |
| ZA (1) | ZA947949B (OSRAM) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9506382D0 (en) * | 1995-03-29 | 1995-05-17 | Boots Co Plc | Pharmaceutical compositions |
| GB9507348D0 (en) * | 1995-04-08 | 1995-05-31 | Knoll Ag | Therapeutic agents |
| US5714607A (en) * | 1995-12-01 | 1998-02-03 | American Cyanamid Company | Process improvement in the synthesis of N- 3-(3-cyano-pyrazolo 1,5-a!pyrimidin-7-yl)phenyl!-N-ethylacetamide |
| AU723098B2 (en) * | 1996-07-25 | 2000-08-17 | Merck Sharp & Dohme Limited | Substituted triazolo-pyridazine derivatives as ligands for GABA receptors |
| GB9617727D0 (en) | 1996-08-23 | 1996-10-02 | Knoll Ag | Process |
| GB9626746D0 (en) * | 1996-12-23 | 1997-02-12 | Knoll Ag | Process |
| DE19706337A1 (de) * | 1997-02-19 | 1998-08-20 | Basf Ag | Verfahren zur Herstellung von enantiomerenreinen Estern |
| DE19706336A1 (de) * | 1997-02-19 | 1998-08-20 | Basf Ag | Verfahren zur Herstellung von enantiomerenreinen Alkoholen |
| DE19707008A1 (de) * | 1997-02-21 | 1998-08-27 | Basf Ag | Verfahren zur Herstellung von enantiomerenreinen Alkoholen |
| AU760688B2 (en) | 1998-10-16 | 2003-05-22 | Merck Sharp & Dohme Limited | Pyrazolo-triazine derivatives as ligands for GABA receptors |
| GB9906130D0 (en) * | 1999-03-18 | 1999-05-12 | Knoll Ag | Compounds for use in therapy |
| GB9906126D0 (en) * | 1999-03-18 | 1999-05-12 | Knoll Ag | Pharmaceutical formulations |
| GB9906124D0 (en) * | 1999-03-18 | 1999-05-12 | Knoll Ag | Therapeutic agent |
| GB9914743D0 (en) * | 1999-06-24 | 1999-08-25 | Knoll Ag | Therapeutic agents |
| JP2004502691A (ja) * | 2000-06-30 | 2004-01-29 | ワイス | 抗癌薬としての置換トリアゾロピリミジン |
| TWI334868B (en) * | 2003-06-03 | 2010-12-21 | Nippon Kayaku Kk | [1,2,4] triazoro [1,5-a] pyrimidine-2-ylurea derivative and use thereof |
| CA2554696C (en) | 2004-02-13 | 2009-06-30 | Warner-Lambert Company Llc | Androgen receptor modulators |
| EP1737813A1 (en) | 2004-04-13 | 2007-01-03 | Warner-Lambert Company LLC | Androgen modulators |
| WO2005102990A1 (en) | 2004-04-22 | 2005-11-03 | Warner-Lambert Company Llc | Androgen modulators |
| TW200724139A (en) | 2005-05-05 | 2007-07-01 | Warner Lambert Co | Androgen modulators |
| ES2451542T3 (es) * | 2008-08-29 | 2014-03-27 | Concert Pharmaceuticals Inc. | Derivados de triazolo-piridazina sustituidos |
| DK2414365T3 (da) * | 2009-04-01 | 2014-03-31 | Aniona Aps | SUBSTITUEREDE [1,2,4]TRIAZOLO[1,5-a]PYRIMIDINER OG ANVENDELSE HERAF SOM KALIUMKANALMODULATORER |
| US20120095025A1 (en) * | 2009-04-01 | 2012-04-19 | Neurosearch A/S | SUBSTITUTED [1,2,4]TRIAZOLO[1,5-a]PYRIMIDINES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS |
| US8685987B2 (en) | 2009-04-01 | 2014-04-01 | Ataxion, Inc. | Substituted [1,2,4]triazolo[1,5-a]pyrimidines and their use as potassium channel modulators |
| WO2020231723A1 (en) | 2019-05-13 | 2020-11-19 | Ecolab Usa Inc. | 1,2,4-triazolo[1,5-a] pyrimidine derivative as copper corrosion inhibitor |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE46306B1 (en) * | 1977-02-11 | 1983-05-04 | Ici Ltd | Safeguarded toxic chemical compositions containing an emetic |
| FR2549834B1 (fr) * | 1983-07-25 | 1985-10-18 | Sanofi Sa | Derives de triazolo-pyrimidine, leur procede de preparation et leur application therapeutique en tant que tonicardiaques |
| WO1989001478A1 (en) * | 1987-08-07 | 1989-02-23 | The Australian National University | ARYLOXY- AND ARALKYLTHIO-IMIDAZO[1,2-b]PYRIDAZINES |
| US5387747A (en) * | 1992-02-24 | 1995-02-07 | Laboratoires Upsa | Triazolopyrimidine derivatives which are angiotensin II receptor antagonists, their methods of preparation and pharmaceutical compositions in which they are present |
-
1993
- 1993-10-13 GB GB939321162A patent/GB9321162D0/en active Pending
-
1994
- 1994-10-11 IN IN982MA1994 patent/IN179169B/en unknown
- 1994-10-12 DK DK94929537T patent/DK0723546T3/da active
- 1994-10-12 AU AU78554/94A patent/AU679573B2/en not_active Ceased
- 1994-10-12 BR BR9407812A patent/BR9407812A/pt not_active Application Discontinuation
- 1994-10-12 RU RU96108927A patent/RU2136684C1/ru active
- 1994-10-12 HU HU9600959A patent/HUT74580A/hu unknown
- 1994-10-12 ES ES94929537T patent/ES2142413T3/es not_active Expired - Lifetime
- 1994-10-12 CA CA002173857A patent/CA2173857A1/en not_active Abandoned
- 1994-10-12 JP JP7511287A patent/JPH09503771A/ja not_active Ceased
- 1994-10-12 SK SK437-96A patent/SK282329B6/sk unknown
- 1994-10-12 US US08/628,662 patent/US5753665A/en not_active Expired - Lifetime
- 1994-10-12 EP EP94929537A patent/EP0723546B1/en not_active Expired - Lifetime
- 1994-10-12 CZ CZ961069A patent/CZ106996A3/cs unknown
- 1994-10-12 PT PT94929537T patent/PT723546E/pt unknown
- 1994-10-12 PL PL94313970A patent/PL177920B1/pl unknown
- 1994-10-12 DE DE69422724T patent/DE69422724T2/de not_active Expired - Lifetime
- 1994-10-12 RO RO96-00795A patent/RO117020B1/ro unknown
- 1994-10-12 IL IL111259A patent/IL111259A/en not_active IP Right Cessation
- 1994-10-12 CN CN94194265A patent/CN1040537C/zh not_active Expired - Fee Related
- 1994-10-12 AT AT94929537T patent/ATE188966T1/de not_active IP Right Cessation
- 1994-10-12 WO PCT/EP1994/003364 patent/WO1995010521A1/en not_active Ceased
- 1994-10-12 NZ NZ274500A patent/NZ274500A/en unknown
- 1994-10-12 UA UA96041428A patent/UA42738C2/uk unknown
- 1994-10-12 ZA ZA947949A patent/ZA947949B/xx unknown
- 1994-10-13 MY MYPI94002724A patent/MY112110A/en unknown
-
1995
- 1995-04-12 TW TW084103591A patent/TW372237B/zh active
-
1996
- 1996-04-09 BG BG100485A patent/BG62405B1/bg unknown
- 1996-04-11 NO NO961435A patent/NO306509B1/no not_active IP Right Cessation
- 1996-04-12 FI FI961630A patent/FI961630A0/fi unknown
-
2000
- 2000-01-26 GR GR20000400175T patent/GR3032480T3/el not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HU9600959D0 (en) | Therapeutic agents | |
| PL308757A1 (en) | Therapeutic agents | |
| PL309347A1 (en) | Application of anticonvulsive agents in therapy of neurological damages caused by or associated with injuries | |
| IL118836A0 (en) | Pharmaceutical compositions comprising S-(-)N-propargyl-1-aminoindan | |
| HU9202429D0 (en) | Method for producing amidic compounds and pharmaceutical prepartives containing said compounds as active agents | |
| CA2148194A1 (en) | Cyclopeptides of the formula i | |
| GB9418912D0 (en) | Pharmaceutically active compounds | |
| GR3036983T3 (en) | Method for increasing libido in post-menopausal women. | |
| GB9309749D0 (en) | Therapeutic agents | |
| NZ333869A (en) | Alpha-amino acid amides and their use in the treatment of neurodegenerative diseases | |
| TW359667B (en) | Tetralines | |
| JO1833B1 (en) | Therapeutic agents | |
| MXPA01009384A (es) | Composiciones farmaceuticas que comprenden un derivado de pirimidina y ciclodextrina. | |
| CA2162706A1 (en) | 1-arylcycloalkyl sulphides, sulphoxides and sulphones for the treatment of depression, anxiety and parkinson's disease |